EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluating the clinical efficacy and safety of concurrent chemoradiotherapy with cisplatin and nab-paclitaxel in postoperative early-stage cervical cancer

Ning Zhao, Yunhai Li, Xue Chen, Jinli Ma, Weiming Luo, Yunhai Li

Journal of Cancer Research and Clinical Oncology · 2024

DOI: 10.1007/s00432-024-05764-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2024. Verfasst von Ning Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Minhang Branch Hospital, Fudan University Shanghai Cancer Center, Shanghai 200240, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Cisplatin, Paclitaxel, Chemoradiotherapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

A preclinical study showed that nab-paclitaxel acted as a radiosensitizer and improved tumor radiotherapy in a supra-additive manner. In this study, we aimed to evaluate the clinical efficacy and safety of concurrent chemoradiotherapy (CCRT) with cisplatin and nab-paclitaxel in postoperative early-stage cervical cancer with an unfavorable prognosis.

Methods

Eligible patients with stage IB1-IIA2 (FIGO 2009) cervical carcinoma were recruited retrospectively between August 2018 to May 2021. Patients in both the cisplatin and nab-paclitaxel groups received postoperative radiotherapy and weekly intravenous cisplatin 40 mg/m 2 or nab-paclitaxel 100 mg concurrently. An analysis of overall survival, progression-free survival, and adverse reactions was conducted.

Results

A total of 105 early-stage cervical cancer patients were included into our study. The median follow-up time was 38.7 months. The 3-year overall survival and progression-free survival in both group was similar. The cycles of chemotherapy in the cisplatin group were less than those in the nab-paclitaxel group (4.5 vs. 5.0; p = 0.001). Patients in the cisplatin group had a significantly higher frequency of hematological adverse events than patients in the nab-paclitaxel group (P < 0.05). Patients in the cisplatin group had a significantly higher frequency of grade 3–4 leukopenia (46.1% vs. 18.9%; P = 0.03), grade 1–2 thrombocytopenia (32.7% vs. 9.5%; P = 0.014) than patients in the nab-paclitaxel group. Gastrointestinal reactions, such as vomiting, nausea, and anorexia were significantly reduced in the nab-paclitaxel group compared with those in the cisplatin group. Regarding the effects on alopecia, the incidence rate of the nab-paclitaxel group was higher than that of the cisplatin group (P = 0.001). There were no differences between the groups in terms of other adverse reactions.

Conclusion

The results of this study indicate that nab-paclitaxel-based concurrent radiotherapy is tolerable and effective, and can be considered an alternative to cisplatin chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsCisplatinPaclitaxelChemoradiotherapyAlbuminsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedRetrospective StudiesAdultNeoplasm StagingAged

Stichwörter der Autor:innen

Cervical cancerCisplatinConcurrent chemoradiotherapyNab-paclitaxelSurvivalToxicity

Substanzen

CisplatinPaclitaxel130-nm albumin-bound paclitaxelAlbumins

Autor:innen und Institutionen

  • Department of Radiation Oncology, Minhang Branch Hospital, Fudan University Shanghai Cancer Center, Shanghai 200240, China.
  • Department of Radiation Oncology, Minhang Branch Hospital, Fudan University Shanghai Cancer Center, Shanghai 200240, China. liyunhai@csco.ac.cn.
  • Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China.

Zitieren

APA

Zhao, N., Li, Y., Chen, X., Ma, J., Luo, W., & Li, Y. (2024). Evaluating the clinical efficacy and safety of concurrent chemoradiotherapy with cisplatin and nab-paclitaxel in postoperative early-stage cervical cancer. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05764-9

Vancouver

Zhao N, Li Y, Chen X, Ma J, Luo W, Li Y. Evaluating the clinical efficacy and safety of concurrent chemoradiotherapy with cisplatin and nab-paclitaxel in postoperative early-stage cervical cancer. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05764-9

BibTeX
@article{Zhao2024,
  author = {Zhao, Ning and Li, Yunhai and Chen, Xue and Ma, Jinli and Luo, Weiming and Li, Yunhai},
  title = {Evaluating the clinical efficacy and safety of concurrent chemoradiotherapy with cisplatin and nab-paclitaxel in postoperative early-stage cervical cancer},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  doi = {10.1007/s00432-024-05764-9}
}
Kostenlos starten →